About Us

At Pretect Devices, we are developing a data-driven solution for neonatal IV monitoring, leveraging our diverse expertise in biomedical engineering, radio astronomy, neonatology, and burns care. Our mission is to protect the smallest and most vulnerable patients from preventable harm during one of the most common yet primitively monitored interventions in the NICU - the intravenous therapy (IV). 

Continuous monitoring is the cornerstone of delivering neonatal critical care. In today’s NICUs, critically ill and prematurely born infants are observed every second for vital parameters such as heart rate, oxygen saturation, and body temperature. Yet, despite this constant vigilance, one of the most significant gaps in neonatal monitoring remains unaddressed — the continuous monitoring of intravenous (IV) therapy.

IV cannulation in neonates is particularly challenging: an average of 7–10 attempts may be required, taking up to an hour to secure access. With extremely small blood volumes, low blood pressure, and hair-thin veins, each insertion carries risk, and even after successful cannulation, 7 out of 10 neonatal IVs will leak or infiltrate.The consequences can be severe. Of all neonatal IV leakages, 4–6% result in extravasation injury — potentially causing long-term tissue damage. IV-related sepsis accounts for nearly 30% of all neonatal deaths. At Pretect Devices, we are dedicated to closing this gap. Our innovation, Vedette, is a neonatal-specific continuous IV monitoring solution designed to support care teams in detecting early signs of infiltration before visible injury occurs. Developed in collaboration with leading NICUs, Vedette integrates seamlessly into existing workflows, providing timely, actionable insights that enhance patient safety, reduce preventable harm, and help healthcare systems balance resources with optimal therapeutic outcomes.